NCT03627182Unknown3 期
Efficacy and Safety of CKD-501 Added to D150 Plus D745 25mg Therapy in Patients With Type 2 Diabetes Inadequately Controlled With D150 Plus D745 25mg: Multi-center, Randomized, Double-blind, Parallel-group, Placebo Control, Therapeutic Confirmatory Study.
适应症
干预措施
相关药物
试验速览
- 阶段
- 3 期
- 入组人数
- 240
- 试验地点
- 1
- 主要终点
- Change from baseline in Glycosylated Hemoglobin (HbA1c)
研究概览
简要总结
The purpose of this study is to prove that the group treated with CKD-501 in combination added that the reduction of glycated hemoglobin superior to placebo treated group added in combination.
详细描述
The aim of this phase III study was to evaluate the efficacy and safety of additional combined CKD-501 administration for 24 weeks in patients with type 2 diabetes who were not adequately controlled for blood glucose by the combination of D150 and D745 25mg .
Furthermore, the extension study for additional 28 weeks is designed to confirm long term safety of actual drug as an oral hypoglycemic agent.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- Triple (Participant, Care Provider, Investigator)
入排标准
- 年龄范围
- 19 Years 至 75 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Between 19 years and 75 years old(male or female)
- •Type Ⅱ diabetes mellitus
- •The patient who has been taking oral hypoglycemic agent at least 8weeks with HbA1c 7 to 10% at screening test
- •Body Mass Index between 21kg/㎡ and 40kg/㎡
- •C-peptide > 1.0 ng/ml
- •Agreement with written informed consent
- •HbA1c 7 to 10% after Run-in period
排除标准
- •Type I diabetes or secondary diabetes
- •Continuous or non continuous treatment(over 7 days) insulin within 3 months prior to screening
- •Treatment with Thiazolidinedione within 3months or patient who has experience such as hypersensitivity reaction, serious adverse event with Thiazolidinedione(TZD), sodium glucose cotransporter 2(SGLT2) inhibitor, Biguanide.
- •Chronic(continuous over 7 days) oral or non oral corticosteroids treatment within 1 month prior to screening
- •Treatment with anti-obesity drugs within 3months
- •Past history: lactic acidosis, genetic problem such as galactose intolerance, etc.
- •Acute or chronic metabolic acidosis including diabetic ketoacidosis
- •History of proliferative diabetic retinopathy
- •Patient with severe infection, severe injury
- •Patients with urinary tract infection including urinary tract sepsis and pyelonephritis
- •Malnutrition, weakness, starvation, hyposthenia, pituitary insufficiency or adrenal insufficiency
- •History of malignant tumor within 5years
- •Drug abuse or history of alcoholism
- •Severe pulmonary dysfunction
- •Severe GI disorder
- •History of myocardial infarction, heart failure, cerebral infarction, cerebral hemorrhage or unstable angina within 6 months
- •Abnormal lab result: ① Fasting Plasma Glucose > 270 mg/dl ② Triglyceride ≥ 500 mg/dl ③ Significant liver dysfunction or AST(Aspartate transaminase)/ALT(Alanine transaminase) ≥ normal range*3 or Total bilirubin ≥ normal range*2 ④ Hemoglobin<10.5g/dL ⑤ Abnormality of thyroid function(significantly out of normal TSH(Thyroid Stimulating Hormone) range)
- •eGFR(Estimated glomerular filtration rate) is less than 60ml/min/1.73m^2
- •Pregnant women or nursing mothers
- •Fertile women who not practice contraception with appropriate methods
- •Participated in other trial within 4 weeks or participating in other trial at present
- •In investigator's judgment
研究组 & 干预措施
CKD-501 0.5mg
Experimental
CKD-501 0.5mg
干预措施: CKD-501 0.5mg (Drug)
Placebo
Placebo Comparator
Placebo
干预措施: Placebo (Drug)
结局指标
主要结局
Change from baseline in Glycosylated Hemoglobin (HbA1c)
时间窗: Baseline, 24 weeks
次要结局
- Change from baseline in HOMA-β(Homeostasis Model Assessment of β-cell function)(Baseline, 24 weeks, 52 weeks)
- Change from baseline in Glycosylated Hemoglobin (HbA1c)(Baseline, 52 weeks)
- Change from baseline in Total Cholesterol(Baseline, 24 weeks, 52 weeks)
- Change from baseline in Triglycerides(Baseline, 24 weeks, 52 weeks)
- Change from baseline in LDL-Cholesterol(Baseline, 24 weeks, 52 weeks)
- Change from baseline in HDL-Cholesterol(Baseline, 24 weeks, 52 weeks)
- Change from baseline in non-HDL-Cholesterol(Baseline, 24 weeks, 52 weeks)
- Change from baseline in Small Dense LDL-Cholesterol(Baseline, 24 weeks, 52 weeks)
- Change from baseline in FFA(Free Fatty Acid)(Baseline, 24 weeks, 52 weeks)
- Change from baseline in Apo-AⅠ(Baseline, 24 weeks, 52 weeks)
- Change from baseline in Apo-B(Baseline, 24 weeks, 52 weeks)
- Change from baseline in Fasting plasma glucose(Baseline, 24 weeks, 52 weeks)
- Change from baseline in QUICKI(Quantitative Insulin Check Index)(Baseline, 24 weeks, 52 weeks)
- Change from baseline in HOMA-IR(Homeostasis Model Assessment of Insulin Resistance)(Baseline, 24 weeks, 52 weeks)
- HbA1c target achievement rate at 24 weeks(HbA1c < 6.5%, 7%)(Baseline, 24 weeks, 52 weeks)
- Change from baseline in Apo-CⅢ(Baseline, 24 weeks, 52 weeks)
- Evaluate safety of CKD-501 from number of participants with adverse events(Baseline, 24 weeks, 52 weeks)
研究者
研究点 (1)
Loading locations...
相似试验
已完成
3 期
Efficacy and Safety of CKD-501 Added to D150 Plus D745 10mg Therapy in Patients With Type 2 DiabetesType2 DiabetesNCT03739125Chong Kun Dang Pharmaceutical226
Unknown
3 期
The Efficacy and Safety of CKD-501 Added to D150 Plus D759 Therapy in Patients With Type 2 DiabetesType2 DiabetesNCT03641352Chong Kun Dang Pharmaceutical240
Unknown
2 期
A Clinical Study to Evaluate the Efficacy and Safety of CKD-351Primary Open Angle GlaucomaOcular HypertensionNCT04448223Chong Kun Dang Pharmaceutical100
Unknown
3 期
A Clinical Study to Evaluate the Efficacy and Safety of CKD-351Ocular HypertensionPrimary Open-angle GlaucomaNCT03762369Chong Kun Dang Pharmaceutical384
已完成
1 期
A Clinical Trial to Investigate the Pharmacokinetic Drug Interaction and Safety of CKD-501, D745 and D150Type 2 DiabetesNCT04334213Chong Kun Dang Pharmaceutical48